- Skip Navigation

Note: This message is displayed if (1) your browser is not standards-compliant or (2) you have you disabled CSS. Read our Policies for more information.

Indiana Professional Licensing Agency


Pursuant to IC 35-48-7-8.1, all errant records must now be corrected and resubmitted within three (3) business days. All controlled substances dispensed, including zero reports, must be reported within three (3) business days.

Effective January 1, 2016, all errant records must be corrected and resubmitted within twenty-four (24) hours. Additionally, all controlled substances dispensed, including zero reports, must be reported within twenty-four (24) hours or by the close of the next business day if the dispenser is closed the day following the dispensing.

Changes to INSPECT Program

  • The U.S. Drug Enforcement Administration (DEA) has published in the Federal Register the Final Rule moving hydrocodone combination products (HCPs) from Schedule III to the more-restrictive Schedule II. This Final Rule imposes the regulatory controls and sanctions applicable to Schedule II substances on those who handle or propose to handle HCPs. This is now effective as of October 6, 2014.  Any prescription written as a Schedule III Hydrocodone Combination Product (HCP) prior to October 6, 2014 may be eligible for refill until April 8, 2015.

  • Tramadol will be federally scheduled (IV) is now effective as of August 18, 2014.  Pharmacies will be required to report all Tramadol prescription records that are more than a 72-hour supply to INSPECT.

  • In addition to this change, INSPECT will be moving closer to real-time reporting over the next year and a half as the program goes to 3 day reporting on 7/1/15, then 24-hour reporting effective 1/1/16.

      Important Announcements

      Key Finding and Recommendations from the Indiana INSPECT Evaluation: Key Findings and Recommendations From A Descriptive Analysis of INSPECT Data

      Dr. Eric Wright with the Indiana University Richard M. Fairbanks School of Public Health at IUPUI presented the final report, “The Indiana INSPECT Evaluation: Key Findings and Recommendations From A Descriptive Analysis of INSPECT Data,” to the Indiana Board of Pharmacy on Monday, March 9, 2015.  The web link provides the full report that examined de-identified INSPECT and provider licensure data from Calendar Years 2011 to 2013.  The data was analyzed to identify trends with controlled substance prescriptions, and the report includes, but is not limited to, analysis on dispensation patterns, doctor shopping and demographic characteristics of opioid prescribers.

      Key Findings and Recommendations from the 2013 IPLA INSPECT Knowledge and Use Survey

      In 2012, the Harold Rogers grant program funded the following study conducted by the Center for Health Policy at the IU Richard M. Fairbanks School of Public Health at IUPUI. The study evaluated the effectiveness of INSPECT and the impact it was making to reduce prescription drug abuse. The Center for Health Policy was solely responsible for analyzing the data and summarizing the findings from the research. The Indiana Professional Licensing Agency, the Indiana State Department of Health and the Attorney General’s Prescription Drug Abuse Prevention Task Force collaborated on this effort. 


        INSPECT is now sharing live data with Utah! - Indiana now shares data with 20 states.

      • Upcoming Training Events

        Click here for more information on the below training opportunities or to reserve a space.

        Currently INSPECT is waiting on grant funding before more regional training sessions are scheduled, however INSPECT offers practice, hospital and physician group trainings, free of charge. Please contact if you would like more information or if you are interested in a private on-site training session for your group or practice. Private on-site training sessions cover the same material mentioned above and include the benefit of having a notary to register interested eligible applicants immediately.